Related Experiment Video
Updated: Jun 21, 2026
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Mutation detection of KRAS by high-resolution melting analysis in Chinese with gastric cancer
Zhi-Min Liu1, Li-Na Liu, Mei Li
1Laboratory Center, The Second Affiliated Hospital of Dalian Medical University, Dalian 116027, PR China.
Abstract:
KRAS proteins play an important role in regulating cell functions. A series of studies has revealed that mutations of KRAS are involved in gastric carcinogenesis. However, mutation status of KRAS remains unclear in gastric cancer from Chinese Mainland. It has been proved that KRAS mutation associates with resistance to epidermal growth factor receptor (EGFR) inhibitors. In this study, KRAS mutations were detected in 52 gastric adenocarcinomas from Northern China. High-resolution melting analysis (HRMA) was used and positive samples were confirmed by direct sequencing. Of the 52 cancers, KRAS mutations were found in 5 (9.6%). All cancers with KRAS mutation were from male patients. Frequencies of KRAS mutation were 14.3% (3/21) and 6.5% (2/31) in differentiated and undifferentiated cancers; 25% (1/4) and 8.3% (4/48) in early and advanced wall penetration cancers; and were 13.3% (2/15) and 8.1% (3/37) in without and with lymph node metastasis cancers, respectively. There was no significant correlation between KRAS mutation and clinicopathological features. There were 3 mutation types in the 5 mutations, including 2 G12D, 1 G12V and 2 G13D mutations. All codon 12 mutations were found in patients with lymph node metastasis and at advanced stage, whereas all codon 13 mutations were found in patients without lymph node metastasis and at early stage. These results support KRAS mutation may only be involved in carcinogenesis of partial gastric cancers and the different mutation types of KRAS may take part in development of gastric cancer at different stages. The resistance of partial gastric cancer patients to EGFR inhibitors may be induced by KRAS mutation.
Insights
KRAS mutations were found in 9.6% of gastric cancers in Northern China. Different KRAS mutation types may influence gastric cancer development and resistance to epidermal growth factor receptor (EGFR) inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS proteins are crucial for cellular functions.
- KRAS mutations are implicated in gastric cancer development.
- KRAS mutation status is not well-defined in Chinese gastric cancer patients.
- KRAS mutations are linked to resistance against epidermal growth factor receptor (EGFR) inhibitors.
Purpose of the Study:
- To investigate the mutation status of KRAS in gastric adenocarcinomas from Northern China.
- To explore the association between KRAS mutations and clinicopathological features.
- To understand the role of different KRAS mutation types in gastric cancer progression and EGFR inhibitor response.
Main Methods:
- KRAS mutations were analyzed in 52 gastric adenocarcinomas using high-resolution melting analysis (HRMA).
- Positive samples were confirmed by direct sequencing.
- Clinicopathological features were correlated with KRAS mutation status.
Main Results:
- KRAS mutations were detected in 5 (9.6%) of the 52 gastric cancers.
- All identified KRAS mutations occurred in male patients.
- No significant correlation was found between KRAS mutation and clinicopathological features.
- Specific KRAS mutations (G12D, G12V) were associated with advanced stages and lymph node metastasis, while others (G13D) were linked to early stages.
Conclusions:
- KRAS mutations may contribute to the carcinogenesis of a subset of gastric cancers.
- Distinct KRAS mutation types might play roles in gastric cancer at different developmental stages.
- KRAS mutations could be a factor in the resistance of some gastric cancer patients to EGFR inhibitors.
